Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclophosphamide + cyclosporine a is a combination of two immunosuppressive drugs used primarily in the management of severe, refractory autoimmune diseases and certain nephrotic syndromes. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death, particularly in rapidly dividing immune cells. Cyclosporine A is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 production. This combination has been studied for use in steroid-resistant nephrotic syndrome (SRNS), acute/subacute interstitial pneumonia associated with dermatomyositis/polymyositis, and other severe autoimmune or inflammatory conditions where monotherapy has failed[1][2][5]. The regimen aims to achieve greater immunosuppression than either drug alone but carries increased risk of infection and toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + cyclosporine a.